Avion Wealth’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Avion Wealth’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-59	Closed	–	–	1247
2023 Q4	$0	Buy	+59	New	+$582	﹤0.01%	1391

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Avion Wealth's EGRX Position: Q1 2024 in Review

Avion Wealth sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 59 shares.

Avion Wealth first reported a position in EGRX in Q4 2023 and held it in 1 quarter. The position peaked at $0 in Q4 2023. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

Avion Wealth reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Avion Wealth sold 59 Eagle Pharmaceuticals, Inc. shares in Q1 2024.
Avion Wealth first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2023 and held it in 1 quarter.
Avion Wealth's Eagle Pharmaceuticals, Inc. position peaked at $0 in Q4 2023.
91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Avion Wealth's 13F filing for Q1 2024, filed 3 May 2024.